Fingerprint
Dive into the research topics of 'Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically